IKT

Inhibikase Therapeutics, Inc. IKT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $3.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$0

Quarter to Jun 30

Net income

$-19.59M

Quarter to Jun 30

Free cash flow

$-12.44M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$240.77M total
Sands Capital Ventures, LLC
$26.43M0.0%
Soleus Capital Management, L.P.
$22.08M0.0%
Trails Edge Capital Partners, LP
$18.37M+12.3%
Fairmount Funds Management LLC
$17.51M0.0%
BlackRock, Inc.
$15.77M+23.2%
ADAR1 Capital Management, LLC
$15.00M+11.8%
Blackstone Inc.
$12.05M0.0%
Siren, L.L.C.
$11.88M0.0%
Commodore Capital LP
$10.96M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$10.02M+10.9%
MILLENNIUM MANAGEMENT LLC
$8.18M+37.6%
Saturn V Capital Management LP
$7.85M+0.1%
Kalehua Capital Management LLC
$7.76M+43.0%
Spruce Street Capital LP
$7.27M0.0%
Squadron Capital Management LLC
$6.09M-14.3%
Nantahala Capital Management, LLC
$5.48M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$5.29M+20.1%
STATE STREET CORP
$3.88M+13.2%
SummitTX Capital, L.P.
$3.61M+16.8%
Integral Health Asset Management, LLC
$2.74M0.0%
Stonepine Capital Management, LLC
$2.38M+157.9%
NORTHERN TRUST CORP
$1.78M+22.2%
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.64M+31.0%
TWO SIGMA INVESTMENTS, LP
$1.64M-4.9%
SPHERA FUNDS MANAGEMENT LTD.
$1.32MNew
See all 106 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IKT

Earnings Per Share

13fpro.ai/company/IKT

Loading ratio trend…

IKT key financials by period

Reported revenue, net income and operating margin by fiscal year, from Inhibikase Therapeutics, Inc.'s annual filings on SEC EDGAR.

Inhibikase Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$260.5K$-19.0M—
FY 2022$123.4K$-18.1M—
FY 2021$3.1M$-14.8M—
FY 2020$698.5K$-2.8M—
Source: IKT filings on SEC EDGAR →

IKT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Inhibikase Therapeutics, Inc. (IKT): stock profile, AI score and financials

Inhibikase Therapeutics, Inc. (IKT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. IKT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $3.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Inhibikase Therapeutics, Inc. reports net income of $-19.6M, free cash flow of $-12.4M. Top institutional holders of IKT by reported 13-F value include Sands Capital Ventures, Soleus Capital Management, L.P., Trails Edge Capital Partners, based on the most recent SEC filings. IKT trades on the Nasdaq exchange and files with the SEC under CIK 1750149. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IKT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibikase Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1750149 →